-
-
-
-
-
-
-
RBC Capital on Axsome Therapeutics (AXSM): 'Still See Upside On ADA Approval And Launch'
-
-
-
-
-
-
-
Truist on Axsome Therapeutics (AXSM): 'We fully expect ADA to be a significantly larger opportunity for AXS-05'
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
-
-
-
-
-
-
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) Reports Prelim Q4 Guidance
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to 'Street High' $170 at H.C. Wainwright
-
-
-
-
-
-
-
UPDATE: Axsome Therapeutics (AXSM) PT Raised to $34 at Ladenburg Thalmann
-
66,490 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

